Livongo Health (NASDAQ:LVGO) released its earnings results on Thursday, September 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.29), Briefing.com reports. The firm had revenue of $40.90 million during the quarter, compared to analysts’ expectations of $39.74 million. The business’s revenue was up 155.6% compared to the same quarter last year. Livongo Health updated its FY 2019 guidance to EPS and its Q3 2019 guidance to EPS.
Livongo Health stock traded up $0.02 during trading hours on Friday, reaching $25.30. 31,000 shares of the stock were exchanged, compared to its average volume of 964,200. Livongo Health has a twelve month low of $22.88 and a twelve month high of $45.68.
In other Livongo Health news, major shareholder Ab (Publ) Kinnevik acquired 3,141,795 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average price of $28.00 per share, for a total transaction of $87,970,260.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hemant Taneja acquired 2,678,571 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average price of $28.00 per share, with a total value of $74,999,988.00. The disclosure for this purchase can be found here. Insiders have acquired 5,826,366 shares of company stock worth $162,980,808 over the last quarter.
LVGO has been the topic of several recent analyst reports. Svb Leerink assumed coverage on Livongo Health in a research report on Monday, August 19th. They set an “outperform” rating and a $50.00 price objective on the stock. Chardan Capital assumed coverage on Livongo Health in a report on Friday, August 16th. They issued a “neutral” rating and a $40.00 target price on the stock. Needham & Company LLC assumed coverage on Livongo Health in a report on Monday, August 19th. They issued a “buy” rating and a $42.00 target price on the stock. Goldman Sachs Group initiated coverage on Livongo Health in a research note on Monday, August 19th. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, KeyCorp initiated coverage on Livongo Health in a research note on Monday, August 19th. They set an “overweight” rating and a $46.00 target price on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $44.20.
About Livongo Health
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
Read More: What are the benefits of investing in REITs?
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.